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DOI 10.1186/s40064-015-0865-2RESEARCH Open AccessPrognostic value of the lymph node ratio for
lymph-node-positive breast cancer- is it just a
denominator problem?
Upali W Jayasinghe1,2*, Nirmala Pathmanathan1, Elisabeth Elder1 and John Boyages3Abstract
Purpose: To examine the prognostic value of lymph node ratio (LNR) for patients with node-positive breast cancer
with varying numbers of minimum nodes removed (>5, > 10 and > 15 total node count).
Methods: This study examined the original histopathological reports of 332 node-positive patients treated in the
state of New South Wales (NSW), Australia between 1 April 1995 and 30 September 1995. The LNR was defined as
the number of positive lymph nodes (LNs) over the total number of LNs removed. The LNR cutoffs were defined as
low-risk, 0.01–0.20; intermediate-risk, 0.21– 0.65; and high-risk, LNR >0.65.
Results: The median follow-up was 10.3 years. In multivariate analysis, LNR was an independent predictor of 10-year
breast cancer specific survival when > 5 nodes were removed. However, LNR was not an independent predictor
when > 15 nodes were removed. In a multivariate analysis the relative risk of death (RR) decreased from 2.20
to 1.05 for intermediate-risk LNR and from 3.07 to 2.64 for high-risk while P values increased from 0.027 to 0.957 for
intermediate-risk LNR and 0.018 to 0.322 for high-risk with the number of nodes removed increasing from> 5 to > 15.
Conclusions: Although LNR is important for patients with low node denominators, for patients with macroscopic
nodal metastases in several nodes following an axillary dissection who have more than 15 nodes dissected, the
oncologist can be satisfied that prognosis, selection of adjuvant chemotherapy and radiotherapy fields can be based
on the numerator of the positive nodes.
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Axillary lymph node status is one of the most important
prognostic factors for breast cancer (Schiffman et al.
2011; Vinh-Hung et al. 2003; Yiangou et al. 1999).
Practice has changed from full dissection and/or radiation
of the axilla (Fisher et al. 1985) to the use of sentinel node
biopsy (SNB) for many patients (Krag et al. 1998). More
recently the Z00011 trial (Giuliano et al. 2010; Giuliano
et al. 2011; Caudle et al. 2011) was conducted to deter-
mine the effects of completion axillary lymph node dissec-
tion (ALND) on overall survival in patients with sentinel
lymph node (SLN) metastases treated with breast conser-
vation and adjuvant therapy including radiotherapy.* Correspondence: upali.jay@unsw.edu.au
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in any medium, provided the original work is pIn an era when ALND is performed selectively in
patients with a high risk of nodal involvement, the ac-
curacy of the surgical procedure assumes greater import-
ance. There is still debate about what constitutes an
adequate axillary dissection in terms of the total number
of lymph nodes removed. The current American Joint
Committee on Cancer (AJCC) Staging System uses the
number of positive LNs and classifies a patient with 1 to
3 positive nodes as having pN1 disease, 4 to 9 positive
nodes as pN2 disease, and 10 or more nodes as pN3
(Singletary et al. 2003; Rabban 2010). However, the num-
ber of involved lymph nodes is also dependant on the
total number of lymph nodes removed and examined,
which in turn depends on surgical and pathologic proce-
dures (Vinh-Hung et al. 2009; Wang et al. 2012). Al-
though some studies noted that six nodes were the
minimum number of nodes needed to adequately assessis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Jayasinghe et al. SpringerPlus  (2015) 4:121 Page 2 of 10the axilla (Katz et al. 2008), it is generally accepted that
greater than 10 LNs are required (National Comprehen-
sive Cancer Network 2013). One study found that at
least five and 10 nodes are required for node-negative
and node-positive patients respectively (Fisher et al.
1981).
Several studies have examined the notion of the LN
ratio (LNR), defined as the number of positive LNs over
the number of LNs removed, as a potential prognostic
factor in breast cancer (Voordeckers et al. 2004; Vinh-
Hung et al. 2010; van der Wal et al. 2002; Truong et al.
2010; Danko et al. 2010). Some studies have demon-
strated that the LNR was useful in estimating prognosis
and should be considered in conjunction with the abso-
lute number of positive lymph nodes in helping guide
decisions for breast cancer management (Chagpar et al.
2006; Chagpar et al. 2007).
The extent of axillary dissection varies from centre to
centre and country to country and of course, surgeon to
surgeon and this has an impact on the risk of loco-
regional recurrence and survival and even account for
variations in the benefit of post-mastectomy radiation
(Boyages & Langlands 1998). An increasing dilemma for
clinicians is whether to give patients with 1–3 N+ post-
mastectomy radiation therapy, particularly if a patient
has had an adequate axillary dissection. In other words,
could the survival and loco-regional control benefit of
radiation be simply due to under-staging and, does the
recent Oxford meta-analysis really mean that every pa-
tient with 1–3 nodes positive require post-mastectomy
radiation (Zhou et al. 2013). Further, there is ongoing
debate, not only about the use of radiation, but also the
areas to be treated particularly with respect to the in-
ternal mammary chain (Vrana et al. 2013).
When ≤ 10 nodes are removed, there is a greater prob-
ability that some patients with ≥ 4 positive nodes will be
misclassified as having one to three positive nodes
(Fisher et al. 1981). In other words patients are poten-
tially understaged. The median number of nodes dis-
sected was 11 and 7, for Canadian (Ragaz et al. 1997)
and Danish (Overgaard et al. 1997) studies respectively
which first reported the potential benefit from post-
mastectomy radiation. A previous study at our institu-
tion examined an average of 25 nodes per case (range,
8–54), and using strict anatomical criteria, the mean
number of LN found in axillary level I, II and III were 8
(range, 2–43), 4 (range, 0–19) and 3 (range, 0–11) re-
spectively (Chua et al. 2002).
Several studies have identified that LNR, categorized
as low risk (LNR = 0.01–0.20), intermediate risk (LNR =
0.21–0.65) and high risk (LNR > 0.65), was better at pre-
dicting breast cancer specific mortality than pN staging
as a way to account for the variability in the nodal count
(the denominator), for various levels of dissection andnumber of positive lymph nodes (the numerator) (Vinh-
Hung et al. 2009; Vinh-Hung et al. 2010; van der Wal
et al. 2002; Danko et al. 2010; Chagpar et al. 2011). In
the current TNM classification system, nodal status is
based on the absolute number of involved lymph nodes
and does not take into account the total number of
lymph nodes removed and assumes that all lymph node
dissections are the same. Although TNM classification
remains the basis of breast cancer staging, LNR may add
important prognostic information. Such a ratio, which
contains both information regarding the number of posi-
tive nodes as well as the denominator as a defacto meas-
ure of the adequacy of the dissection, may be superior to
the current AJCC staging system in terms of predicting
outcomes (Chagpar et al. 2011).
Few studies have examined LNR in patients with vary-
ing total numbers of lymph nodes removed. The aim of
this study was to examine whether the prognostic value
of LNR depends on the number of nodes removed (>5, >
10 and > 15) using data from a statewide population
study involving 154 surgeons and 58 pathology practices
in Australia’s largest state.
Method
Patient selection
The population studied included 848 consecutive pa-
tients with invasive breast cancer who had original histo-
logical reports and treated in New South Wales (NSW),
Australia between 1 April 1995 and 30 September 1995.
This was a population-based study collecting data from
multiple treatment centers via a notification process in-
volving a central cancer registry. Only patients who had
treatment to their breast combined with axillary clear-
ance surgery were included (n = 848).
A total of 154 surgeons performed surgery on 848
patients using 58 different pathology practices. There
were 332 nodes positive patients, 515 node-negative
and an unknown number of nodes examined (n = 1),
(total including nodes negative is 848) during the six
months period. Patterns of care to the breast in this
cohort have been previously published (Boyages et al.
2010). Patients with < 6 nodes identified (n = 7) or
node-negative breast cancer (n = 515) were excluded
from the analysis.
The study, therefore included, three hundred and
twenty five lymph node-positive cases with > 5 nodes
dissected, 262 with > 10 nodes and 149 with > 15 nodes
in the analysis. All node-positive patients who had
surgery to their breast and axillary clearance surgery
with > 5 nodes removed (34% had conservative treatment
and 66% mastectomy) were included. One hundred and
thirty six had radiation therapy (85% of breast conserva-
tion patients and 20% of mastectomy patients) and 181
had chemotherapy. The median number of axillary lymph
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technique was not used at that time.
Data analysis
The New South Wales (NSW) Central Cancer Registry
(CCR) maintains a register of all cases of cancer diag-
nosed in NSW since the beginning of 1972. All cases of
breast cancer not known to be dead by the NSW CCR
were matched against the death records from the NSW
Registry of Births, Deaths and Marriages, enhanced by
information obtained from the Australian Bureau of
Statistics. Ten-year breast cancer survival data of the
study group were provided by the NSW CCR. Follow-up
time was calculated from the date of first treatment
(surgery) to the date of last follow-up or death. The
median follow-up was 10.3 years (interquartile range,
5.2–10.5 years).
The LNR was calculated as the total number of posi-
tive lymph nodes divided by the total number of lymph
nodes found and examined (the denominator). The co-
hort was then divided into 3 groups based on established
LNR cutoffs (Vinh-Hung et al. 2009; Vinh-Hung et al.
2010; van der Wal et al. 2002; Danko et al. 2010;
Chagpar et al. 2011). Accordingly, in this study, the LNR
cutoffs were defined as low-risk, 0.01–0.20; intermediate-
risk, 0.21– 0.65; and high-risk, >0.65. We examined the
prognostic value of lymph node ratio (LNR) for patients
with node-positive breast cancer with varying numbers of
minimum nodes removed (>5, > 10 and > 15 total node
count). We also examined the impact of minimum num-
ber of lymph nodes removed (all patients, ≤10 or >10
and ≤ 15 or >15) to compare the performance of LNR as
prognostic indicators.
Comparison of categories within a characteristic was
carried out with the Pearson Chi-square test and, if any
of the expected frequencies was less than five, the
Fisher exact test was used. A preliminary univariate
survival analysis was performed with the Kaplan-Meier
method or Cox proportional hazard regression and
groups were compared with the log-rank test. Signifi-
cant or marginally significant predictors in the univari-
ate analysis were included in the multivariate analysis.
The independent prognostic effect of LNR was investi-
gated using Cox proportional hazard regression, adjusting
for pN stage, age (<40, ≥ 40), pathological tumour size
(≤20 mm, or > 20 mm), histological grade (1, 2 or 3),
ER status (negative or positive) and chemotherapy
(no or yes). Radiation therapy (no or yes) and hor-
mone therapy (no or yes) were not significant in
univariate analysis. All statistical analyses were per-
formed using SPSS statistical software (IBM SPSS
Statistics version 19, New York, USA). Survival plots
were generated using SAS statistical software (version
9.3; SAS Institute, Cary, NC). Our study was approvedby the NSW Population and Health Services Research
Ethics Committee.
Results
The mean age of patients at diagnosis was 56 years
(range, 25–91 years). The clinical and pathological char-
acteristics of patients and treatment of patients are
shown in Table 1. Compared to patients with low-risk
LNR, patients with intermediate- or high-risk LNR were
more likely to have pathological tumour size over
20 mm (41% vs 67%, P < 0.001), more likely to be grade
3 (54% high-risk vs 36% low-risk, P = 0.02), have
pN2 (4-9 N+) disease (28.2% high-risk vs 2.7% low-
risk, P < 0.001) or pN3 (≥10 N+) 71.8% high-risk vs
13.1% intermediate-risk, P < 0.001), radiation therapy
(33% vs 54%, P = 0.001) and chemotherapy (50% vs >60%,
P = 0.007) (Table 1). The relationship with other patient or
tumour characteristics did not vary by LNR groups. In
particular, LNR was not different by age at diagnosis. Simi-
larly, distribution of ER and hormone therapy over the
LNR groups was similar (Table 1).
At a median follow-up of 10.3 years, 37 of 187 patients
(19.8%) with low-risk LNR have died of breast cancer
compared to 46 of 99 (46.5%) with intermediate-risk and
23 of 39 (59.0%) with high-risk LNR (P < 0.001). Table 2
shows two scenarios using a denominator of 10 or 15
nodes identified in the final pathology report. Although
for patients with 1–3 nodes positive, increasing LNR
was associated with increasing mortality when ≤ 10 (low-
risk: 16.7%; intermediate risk: 41.2%) or >10 nodes were
removed (low-risk: 19.7%; intermediate risk: 45.5%),
LNR lost its significance (low risk: 15.9% and no other
risk categories) when more than 15 nodes were dissected.
Figure 1a shows, that for patients with pN1 (1-3 N+) dis-
ease, patients with more than 15 nodes dissected had a
10-year breast cancer-specific survival of 84% compared
to 71% when up to 15 nodes were dissected (p = 0.035).
Figure 1b shows the corresponding 10-year breast cancer
specific survival rates for all possible combinations of
LNR for patients with pN1 (1-3 N+). The best 10-year
breast cancer specific survival rate was 84% for a low LNR
and high nodal denominator (>15 nodes identified). In
contrast, for pN1 patients with up to 15 nodes dissected
and a low LNR the 10-year survival rate was 76% but
dropped to 55% for an intermediate LNR (p = 0.024).
There were no patients with a high LNR in the pN1
subgroup.
For patients with 10 or more positive nodes (pN3)
mortality was over 60% irrespective of LNR in a clinical
setting where most oncologists would advise post-
mastectomy RT. For pN2 disease (4–9 nodes positive),
LNR only made a difference in the setting where ≤ 10
nodes were dissected again implying that if the denom-
inator increased to 15 or more, more patients would
Table 1 Clinicopathologic characteristics of 325 women with lymph node-positive breast cancer according to lymph
node ratio (LNR)
Characteristic Lymph node ratio
Low-risk Intermediate-risk High-risk All
(≤0.20) (>0.20 & ≤0.65) (>0.65)
(n = 187) (n = 99) (n = 39) (n = 325)
P value No. (%) No. (%) No. (%) No. (%)
Age, yrs 0.622
<40 22 11.8 8 8.1 3 7.7 33 10.2
≥40 165 88.2 91 91.9 36 92.3 292 89.8
Tumour size, mm <0.001
0–20 110 58.8 33 33.3 13 33.3 156 48.0
>20 77 41.2 66 66.7 26 66.7 169 52.0
Histological grade 0.063
1 (0.047) 30 16.0 8 8.1 4 10.3 42 12.9
2 74 39.6 40 40.4 8 20.5 122 37.5
3 68 36.4 43 43.4 21 53.8 132 40.6
Unknown 15 8.0 8 8.1 6 15.4 29 8.9
ER status 0.362
Negative (0.869) 15 8.0 7 7.1 2 5.1 24 7.4
Positive 48 25.7 16 16.2 7 17.9 71 21.8
Unknown 124 66.3 76 76.8 30 76.9 230 70.8
No. of nodes removed 0.249
6–10 30 16.0 26 26.3 7 17.9 63 19.4
11–15 64 34.2 35 35.4 14 35.9 113 34.8
>15 93 49.7 38 38.4 18 46.2 149 45.8
pN stage <0.001
pN1 (1–3) 182 97.3 28 28.3 0 0.0 210 64.6
pN2 (4–9) 5 2.7 58 58.6 11 28.2 74 22.8
pN3 (≥10) 0 0.0 13 13.1 28 71.8 41 12.6
Radiation therapy 0.001
No 125 66.8 45 45.9 18 46.2 188 58.0
Yes 62 33.2 53 54.1 21 53.8 136 42.0
Chemotherapy 0.007
No 92 50.3 30 30.9 15 39.5 137 43.1
Yes 91 49.7 67 69.1 23 60.5 181 56.9
Hormone therapy 0.278
No 79 42.2 33 33.3 13 33.3 125 38.5
Yes 108 57.8 66 66.7 26 66.7 200 61.5
P values are for comparison of categories of each variable by lymph node ratio using the Pearson chi-square test or the Fisher exact test. For characteristics with
an unknown category the P values without unknown category are shown within parentheses. Patients with > 5 nodes removed included in the table.
Missing values: Radiation therapy = 1, Chemotherapy = 7.
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(Table 2).
We also analyzed LNR by number of nodes dissected
(all patients or ≤ 15 or >15) (Table 3). Although increas-
ing LNR was a predictor of breast cancer mortality for
all patients by univariate or multivariate analysis, it onceagain lost its significance when more than 15 nodes were
identified (Table 3). In a multivariate analysis the relative
risk of death (RR) decreased from 2.20 to 1.05 for
intermediate-risk LNR and from 3.07 to 2.64 for high-
risk while P values increased from 0.027 to 0.957 for
intermediate-risk LNR and 0.018 to 0.322 for high-risk
Table 2 Percentage of breast cancer deaths by LNR and pN stage for varying total numbers of nodes removed
pN stage Nodes removed Number of deaths/total (%) for LNR
Low-risk Intermediate-risk High-risk All
(≤0.20) (>0.20 & ≤0.65) (>0.65)
Nodes removed ≤10 and >10
pN1 (1–3) ≤10 5/30 (16.7) 7/17 (41.2) * 12/47 (25.5)
>10 30/152 (19.7) 5/11 (45.5) * 35/163 (21.5)
pN2 (4–9) ≤ 10 * 2/9 (22.2) 3/7 (42.9) 5/16 (31.3)
> 10 2/5 (40.0) 24/49 (49.0) 2/4 (50.0) 28/58 (48.3)
pN3 (≥10) ≤10 * * * *
>10 * 8/13 (61.5) 18/28 (64.3) 26/41 (63.4)
Nodes removed ≤15 and >15
pN1 (1–3) ≤15 21/94 (22.3) 12/28 (42.9) * 33/122 (27.0)
>15 14/88 (15.9) * * 14/88 (15.9)
pN2 (4–9) ≤ 15 * 15/33 (45.5) 5/11 (45.5) 20/44 (45.5)
> 15 2/5 (40.0) 11/25 (44.0) * 13/30 (43.3)
pN3 (≥10) ≤15 * * 5/10 (50.0) 5/10 (50.0)
>15 * 8/13 (61.5) 13/18 (72.2) 21/31 (67.7)
*no cases from this category.
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to > 15.
Discussion
LNR has been widely demonstrated to be a useful alter-
native to predict survival in many cancers including lung
cancer (Matsuguma et al. 2012; Jonnalagadda et al.
2011), colon cancer (Greenberg et al. 2011; Berger et al.
2005), pancreas (Berger et al. 2004), bladder (Herr 2003),
gastric cancer (Tong et al. 2011; Hong et al. 2011) and
particular breast cancer (Schiffman et al. 2011; Vinh-Hung
et al. 2009; Danko et al. 2010; Chagpar et al. 2011). In con-
trast to many other studies, we found that LNR was not im-
portant if an adequate axillary dissection was performed.
We hypothesise that LNR is a problem of the denominator.Figure 1 Kaplan-Meier breast cancer specific survival estimates accor
pN1 (1–3) stage. Numbers in parentheses indicate total number and numb
Numbers in parentheses indicate total number and number at risk. There w
pN1 stage were low-risk LNR for > 15 nodes removed. P values are from thWhen patients with breast cancer have a nodal dissection
identifying more than 15 nodes, LNR loses its significance.
Woodward et al. (2006) conducted a systematic review
based on 24 studies published from 1994 to 2005 total-
ing 32,299 patients supporting the greater prognostic
value of LNR compared to number of involved nodes.
Table 4 shows the prognostic value of LNR for more re-
cent studies published since 2008 and these studies
again confirmed the superiority of LNR (Schiffman et al.
2011; Vinh-Hung et al. 2009; Danko et al. 2010; Chagpar
et al. 2011; Saxena et al. 2012; Truong et al. 2008; Li
et al. 2012; Duraker et al. 2013; Dings et al. 2013). How-
ever, in these studies all patients were included in the
analysis and the denominator of LNR (number of nodes
removed) starting from one node found leading to highding to the number of nodes removed. (a) shows overall survival for
er at risk. (b) shows overall survival for pN1 (1–3) stage by LNR.
ere no cases from high risk LNR for ≤ 15 nodes removed. All cases for
e log rank-test with intermediate LNR as the reference.
Table 3 Results of univariate and multivariate survival analysis at 10-year follow up
All patients (n = 318) lymph nodes removed ≤15
(n = 172)










Factor RR (95% CI) P RR (95% CI) P No. RR (95% CI) P No. RR (95% CI) P
LNR
≤0.20 1.00 1.00 92 1.00 93 1
>0.2–0.65 2.91 (1.90–4.47) <.001 2.20 (1.09–4.41) 0.027 59 1.94 (0.91–4.12) 0.085 38 1.05 (0.20–5.54) 0.957
>0.65 4.31 (2.56–7.25) <.001 3.07 (1.21–7.80) 0.018 21 2.03 (0.56–7.33) 0.282 18 2.64 (0.39–18.04) 0.322
pN stage
pN1 (1–3) 1.00 1.00 118 1.00 88 1
pN2 (4–9) 2.52 (1.62–3.91) <.001 1.28 (0.63–2.60) 0.500 44 1.15 (0.51–2.60) 0.745 30 4.31 (0.88–21.20) 0.073
pN3 (≥10) 3.85 (2.38–6.21) <.001 1.31 (0.56–3.08) 0.533 10 1.03 (0.23–4.64) 0.970 31 5.03 (0.86–29.45) 0.073
Age at diagnosis
<40 1.68 (0.99–2.86) 0.056 1.82 (1.03–3.22) 0.038 15 1.49 (0.61–3.66) 0.384 18 3.43 (1.53–7.69) 0.003
≥40 1.00 1.00 157 1.00 131 1.00
Tumour size, mm
1–20 1.00 1.00 83 1.00 72 1.00
>20 2.25 (1.51–3.37) <.001 1.52 (0.99–2.35) 0.058 89 1.95 (1.08–3.51) 0.027 77 0.76 (0.35–1.64) 0.487
Histological grade
1 1.00 1.00 22 1.00 20 1.00
2 2.16 (0.97–4.83) 0.060 1.84 (0.81–4.18) 0.143 58 2.18 (0.63–7.60) 0.221 62 1.79 (0.57–5.60) 0.318
3 3.21 (1.46–7.05) 0.004 2.21 (0.98–4.95) 0.055 77 3.73 (1.13–12.32) 0.031 53 1.40 (0.42–4.60) 0.584
Unknown 1.35 (0.45–4.02) 0.590 1.03 (0.34–3.11) 0.958 15 1.51 (0.30–7.60) 0.619 14 0.73 (0.15–3.69) 0.706
ER
Negative 1.00 1.00 11 1.00 13 1.00
Positive 0.37 (0.18–0.77) 0.008 0.49 (0.23–1.06) 0.071 36 0.59 (0.19–1.87) 0.367 35 0.20 (0.06–0.65) 0.007
Unknown 0.59 (0.32–1.09) 0.091 0.60 (0.32–1.13) 0.115 125 0.76 (0.29–1.95) 0.562 101 0.26 (0.10–0.66) 0.005
Chemotherapy
No 1.00 1.00 96 1.00 61 1.00
Yes 1.58 (1.05–2.37) 0.028 1.04 (0.67–1.61) 0.860 76 1.24 (0.69–2.22) 0.480 85 0.61 (0.29–1.30) 0.202
RR: Relative risk of dying; 95% CI: 95% confidence interval of relative risk.
P value is for comparison of each category with the reference category.
Number in each category is shown in Table 1. Seven missing values for chemotherapy.
Radiation therapy (P = 0.587) and hormone therapy (P = 0.762) are not significant in univariate analysis and not included in multivariate analysis.
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vival simply because of under-staging of the axilla. Similar
to our study all of these studies but one examined the
prognostic value of LNR after adjustment for pN stage.
We found that LNR was no longer significant when the
denominator was >10 (Tables 2 and 3) and particularly
when >15 nodes were identified (Table 3).
The likelihood of finding positive nodes in the axilla
increases with the number of nodes removed, similarly
the likelihood of having residual disease in the axilla de-
creases with more extensive dissection (Krag & Single
2003; McMasters 2003). In this study, LNR appeared to
be important only for patients who had <10 nodes iden-
tified by the pathologist after an axillary dissection. Oncethe level of dissection of the axilla increased to 10 or
more nodes and particularly more than 15 nodes, LNR
was not significant in a multivariate analysis.
The study demonstrates that the LNR predicted sur-
vival more accurately than pN stage for all patients and
when both ≤ 15 or > 15 nodes removed were included in
the analysis (Table 3) consistent with other studies in
which all patients with varying node counts were included
in the analysis (Vinh-Hung et al. 2009; Voordeckers et al.
2004; Truong et al. 2005; Ahn et al. 2011). In our series,
almost half of our patients (45.9%) had a denominator
of >15 nodes removed. In a large study from the
Netherlands, 37.4% of patients had > 15 nodes removed
(Dings et al. 2013). In a multivariate analysis relative
Table 4 Recent studies (2008–2013) of ratios of involved nodes in breast cancer








Outcome and Prognostic role





Truong et al. 2008 1988–1997 4571 T1–T2 ≤0.25, 14 years BCCS and OS significant 15 (1–50) Population
Node-positive >0.25
Vinh-Hung et al. 2009 1980-2004 1829 T1–T3 1. LNR, continuous. 10 years BCSS significant for continuous and
categorical LNR
14 (1–X) Population
Node-positive 2. ≤0.20,0.21-0.65, >0.65
Danko et al. 2010 1985-2005 1788 T1–T3 ≤0.20,0.21-0.65, >0.65 10 years DFS and OS significant 17 (1–57) Institution
Node-positive
Schiffman et al. 2011 1996-2007 556 T1–T3 ≤0.20,0.21-0.65, >0.65 5 years DFS and OS significant 3 (1–52) Population
Node-positive
Chagpar et al. 2011 1956-1982 319 T1–T3 ≤0.20,0.21-0.65, >0.65 40 years OS significant 13 (1–48) Institution
Node-positive
Li et al. 2012 1998-2000 127 T1–T4 LNR, continuous. 10.9 years OS significant X Institution
Node-positive
Saxena et al. 2012 1990-2007 1589 T1–T3 ≤ .20,0.21-0.65, >0.65 5 years OS significant 15 (1–X) Institution
Node-positive
Duraker et al. 2013 1993–2002 2151 T1–T3 ≤ .20,0.21-0.65, >0.65 7 years DFS significant 14 (1–46) Institution
Node-positive
Dings et al. 2013 1999-2005 25315 T1–T3 ≤ .20,0.21-0.65, >0.65 10 years OS significant 14 (1–90) Population
Node-positive




2. BCSS significant for all patients.
Notes: *Node-positive patients were considered if possible.
BCSS-breast cancer specific survival. DFS-disease-free survival.
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(4-9 N+) and from 1.31 to 5.03 for pN3 (≥10 N+) and P
values decreased from 0.5 to 0.073 for pN2 and 0.53 to
0.073 for pN3 with the number of nodes removed in-
creasing from > 5 to > 15 (Table 3).
It is likely that some patients from the intermediate-
risk LNR were understaged as pN1 stage as a result of
the small number of nodes removed (Table 2). Further,
this conclusion is supported by the number of positive
nodes in the intermediate-risk LNR (median = 3, range,
2–3) for groups where ≤ 10 or ≤ 15 nodes removed.
When ≤ 15 nodes are removed, there is a greater prob-
ability that some patients with ≥ 4 positive nodes will be
misclassified as having one to three positive nodes. This
is in contrast to those patients where > 15 nodes are re-
moved where all pN1 patients were from the low-risk
LNR.
Most studies of LNR in breast cancer are single-
institution studies that create their own LNR groupings
based on their institution’s data (Katz et al. 2008;
Voordeckers et al. 2004; van der Wal et al. 2002). The
number of lymph nodes removed and examined is highly
dependent on surgical technique and expertise, the insti-
tution’s protocol for identifying lymph nodes and the
pathologists’ experience (Schaapveld et al. 2004). Our
study is one of the few population based studies that ex-
amined the LNR risk categories established by previous
studies (Vinh-Hung et al. 2009; Vinh-Hung et al. 2010;
van der Wal et al. 2002; Danko et al. 2010; Chagpar
et al. 2011) and involved a large number of surgeons
with varying expertise in performing axillary clearance.
The duration of follow-up in our study is longer than
that in many other studies (median = 10.3 years), which
increases the ability to assess the prognostic value of the
variables being investigated. Other advantages of our
study are the larger median number of nodes removed
(n = 15) and accurate follow up data with breast cancer
specific survival based on information received from a
centralised cancer registry which included information
on cause of death.
Some authors argue that the additional information
from performance of completion ALND after positive
SLN biopsy may benefit patients by guiding decisions
about adjuvant chemotherapy. For the approximately
one-half of patients in whom there is residual nodal dis-
ease, it is also argued that complete ALND can influence
survival via local-regional control of the axilla, thereby
eliminating a potential site of recurrent disease and, ul-
timately, a source for distant disease (Straver et al. 2010;
Kothari et al. 2012; Sosa et al. 1998). The standard of
care for breast cancer patients with sentinel lymph node
(SLN) metastases includes complete ALND (Van Zee
et al. 2003). The Z-0011 trial has advocated that ALND
is not necessary if < 3 nodes are involved (Giuliano et al.2010). Giuliano et al. (2011) summarized total nodal in-
volvement in ALND and SLND alone groups, 21.0% of
patients undergoing ALND had 3 or more involved
nodes compared with 3.7% undergoing SLND alone
(Giuliano et al. 2011). Completion ALND quantifies total
nodal burden, defines prognosis and can determine adju-
vant treatments in addition to maximising local disease
control (Kothari et al. 2012). However, the Z-0011 data
has questioned the need for completion ALND for early
node-positive breast cancer treated with conservation,
RT and optimal systemic therapy. Thus our data, need to
be placed into context of changes in recent strategy par-
ticularly for older patients with smaller primary tumors
and low sentinel node positivity particularly for luminal
A tumors where RT to the axilla is also given (Jagsi et al.
2014). However, for patients with macroscopic nodal
metastases in several nodes following an axillary dissec-
tion who have more than 15 nodes dissected, the oncolo-
gist can be satisfied that prognosis, selection of adjuvant
chemotherapy and radiotherapy fields can be based on the
numerator of the positive nodes. When patients have low
node denominators and higher numerators, our data sug-
gests that LNR is important and treatment selection may
need to be intensified to take into account potential
understaging of the axilla.
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